Discovered and successfully isolated in 2004 from a healthy human fecal sample by researchers including Derrien and de Vos, Akkermansia muciniphila is an oval-shaped, non-motile, non-spore-forming, Gram-negative, and strictly anaerobic bacterium belonging to the Verrucomicrobia phylum [1][2][3][4]. It is uniquely adapted to thrive in the nutrient-rich mucus layer of the human gastrointestinal tract. Unlike many transient probiotics, A. muciniphila is an endogenous commensal microbe, representing roughly 1% to 5% of the total intestinal microbial community in healthy adults, and naturally colonizes the infant gut within the first year of life [1:1][5][6][7].
The defining characteristic of A. muciniphila is its ability to utilize host-derived mucin glycoproteins as its sole source of carbon and nitrogen [3:1][5:1][8]. Far from being parasitic, this mucin-degrading activity triggers a beneficial feedback loop that thickens the host's mucus layer, thereby preventing "leaky gut" syndrome and halting the translocation of lipopolysaccharides (LPS) into the bloodstream [9][10]. Because its abundance is inversely correlated with aging, obesity, untreated type 2 diabetes mellitus, and inflammatory diseases, it has earned the moniker of a "Next-Generation Probiotic" (NGP) and is viewed as a highly promising therapeutic target for metabolic and systemic disorders [5:2][11][12][13].
To evaluate the clinical efficacy of A. muciniphila, this report strictly adheres to the pyramid of evidence-based medicine:
Priority in the following sections is given to human in vivo data to provide the most scientifically robust analysis possible.
The most significant Tier 1 evidence regarding the metabolic applications of A. muciniphila stems from a landmark randomized, double-blind, placebo-controlled proof-of-concept study led by Depommier et al. (published in Nature Medicine, 2019) [12:1][14][15][16].
The Depommier Trial (NCT02637115):
This trial enrolled 40 overweight or obese, insulin-resistant human volunteers. Participants were randomized to receive a daily oral supplement of either a placebo, live A. muciniphila ( bacteria), or pasteurized A. muciniphila ( bacteria) for three months [12:2][14:1].
Systematic reviews and meta-analyses synthesizing human and animal data further solidify these findings. Multiple reviews (e.g., Asghari et al., 2025; Payahoo et al., 2019) conclude that A. muciniphila operates as an essential regulator of host glucose and energy homeostasis, modulating the endocannabinoid (eCB) system and upregulating hepatic GLUT2 gene expression to improve glucose transport [5:3][17][18].
In the realm of immuno-oncology (Tier 2 and Tier 1 evidence), A. muciniphila has revolutionized our understanding of the microbiome-tumor-immunity axis. Immunotherapy, specifically immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway, is highly effective but fails in a significant percentage of patients. Research has identified gut dysbiosis, often exacerbated by systemic antibiotics, as a primary culprit for treatment failure [19][20].
The Routy and Derosa Cohorts:
A seminal 2018 study in Science by Routy et al. utilized metagenomic sequencing of stool samples from patients with advanced non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) [19:1][20:1][21]. They discovered a direct correlation between the relative abundance of A. muciniphila and positive clinical responses to anti-PD-1 therapy. To prove causality, researchers performed fecal microbiota transplantation (FMT) from human responders and non-responders into germ-free mice. Mice receiving the non-responder microbiome failed to respond to PD-1 blockade; however, when subsequently supplemented with oral A. muciniphila, the efficacy of the immunotherapy was completely restored [20:2][21:1]. This was mediated by increased recruitment of CCR9+CXCR3+CD4+ T lymphocytes into the tumor microenvironment [21:2].
A larger prospective validation study by Derosa et al. (Nature Medicine, 2022) analyzed 338 patients with advanced NSCLC. Baseline intestinal Akkermansia was independently associated with increased objective response rates (ORR) and improved overall survival, regardless of tumor PD-L1 expression levels [22][23][24].
Registered Clinical Trials in Oncology:
Based on these findings, registered clinical trials are currently active:
Emerging evidence (Tier 2/3) points toward the psychobiotic potential of A. muciniphila. By improving gut barrier integrity, the bacterium limits systemic neuroinflammation. Furthermore, it regulates host intestinal serotonin (5-HT) systems and influences Brain-Derived Neurotrophic Factor (BDNF) [28][29]. An ongoing proof-of-concept clinical trial (NCT05738746) is investigating the daily administration of pasteurized A. muciniphila to mitigate the somatic and psychological symptoms of chronic stress in healthy human participants, utilizing its ability to modulate the microbiota-gut-brain axis [30][31].
Understanding how a single microbe exerts such vast systemic influence requires a deep dive into its distinct molecular machinery.
It seems paradoxical that a bacterium whose primary function is to "eat" the host's intestinal mucus layer actually strengthens the gut barrier. However, A. muciniphila degrades complex mucin glycoproteins using a highly specialized enzymatic arsenal, including glycosyl hydrolases, sialidases, and sulfatases [3:2][8:1].
This degradation serves several purposes:
Perhaps the most crucial breakthrough in Akkermansia research was the identification of Amuc_1100, an abundant, pilus-like outer membrane protein [10:1][28:1][32][33][34].
Glucagon-like peptide-1 (GLP-1) is a critical incretin hormone secreted by enteroendocrine L-cells in the ileum and colon. GLP-1 stimulates insulin release, delays gastric emptying, and regulates satiety—making it the target of blockbuster weight-loss drugs (e.g., semaglutide).
A. muciniphila naturally stimulates endogenous GLP-1 secretion through multiple synergistic pathways:
Traditionally, probiotics are defined as live microorganisms. However, the paradigm shifted violently with A. muciniphila. In multiple Tier 1 and Tier 2 models, including the pivotal Depommier trial, pasteurized (heat-killed) A. muciniphila proved equivalent or superior to the live form in mitigating insulin resistance, lowering cholesterol, and reducing adiposity [11:3][12:6][14:3][15:2][29:2].
Why does a dead bacterium work?
Note on Live Forms: While pasteurization optimizes systemic metabolic signaling via Amuc_1100, live forms are still preferred for active mucin degradation, SCFA synthesis, and prolonged ecological restoration of the gut microbiome [35:1].
As an endogenous human gut resident, A. muciniphila has generally shown an exceptional safety profile. However, because it was only isolated in 2004, it lacks the historical "Qualified Presumption of Safety" (QPS) status assigned to traditional microbes like Lactobacillus [1:2][38]. Consequently, regulatory bodies required extensive novel toxicology testing.
In 2021, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) officially authorized pasteurized Akkermansia muciniphila (strain MucT / ATCC BAA-835) as a Novel Food [37:2][38:1][39].
Subsequent safety re-evaluations in 2024 and 2025 expanded these guidelines based on rigorous toxicological and human clinical data [40][41][42][43]:
In the United States, targeted strains of A. muciniphila and specific formulations (such as those developed by Pendulum Therapeutics) are marketed under self-affirmed GRAS status, permitting their use as medical foods and dietary supplements under physician supervision [7:2][44][45].
Bringing a strict anaerobe to the commercial market poses severe manufacturing hurdles. Exposure to atmospheric oxygen rapidly kills A. muciniphila. Commercial entities have had to pioneer anaerobic fermentation and freeze-drying techniques, often utilizing acid-resistant, delayed-release capsules to protect the bacteria through the stomach [46].
The industry standard for measuring probiotics is the Colony Forming Unit (CFU), which relies on growing live bacteria on an agar petri dish [44:1][47]. However, strictly anaerobic and fastidious bacteria like Akkermansia often fail to culture reliably on standard agar, even when metabolically active [48].
To solve this, leading microbiome companies (e.g., Pendulum) utilize Active Fluorescent Units (AFU). AFU is measured using high-throughput flow cytometry combined with fluorescent membrane-integrity dyes. This method counts every individual living cell—as well as cells that are viable but non-culturable (damaged but metabolically active)—providing a vastly more accurate quantification of the true bioactive dose [44:2][46:1][47:1][48:1].
Pendulum Therapeutics holds exclusive patents for specific A. muciniphila strains and offers two distinct clinical formulations targeting metabolic health:
1. Pendulum Akkermansia [46:2][47:2][48:2][49]
2. Pendulum Glucose Control (Medical Probiotic) [45:1][50][51][52][53]
Despite the overwhelming promise of Akkermansia muciniphila, several scientific and clinical gaps remain:
Akkermansia muciniphila represents a watershed moment in microbiology and gastroenterology. As a unique mucin-degrader, it fundamentally rewires our understanding of host-microbe symbiosis. The discovery that its pasteurized form, driven by the thermostable Amuc_1100 protein, can potently modulate TLR2 receptors, improve insulin sensitivity, and enhance gut barrier function without requiring live colonization opens up the modern era of "postbiotics." Furthermore, its potential to rescue non-responders in oncological PD-1 immunotherapy places Akkermansia at the absolute cutting edge of precision medicine. Supported by stringent EFSA safety authorizations and advanced AFU quantification methodologies, A. muciniphila safely and effectively transitions microbiome science out of the laboratory and into targeted metabolic and immunological therapies.
frontiersin.org. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2017.01725/full ↩︎ ↩︎ ↩︎ ↩︎
food.gov.uk. https://science.food.gov.uk/article/125531-safety-assessment-on-pasteurised-akkermansia-muciniphila-used-as-a-food-supplement-rp1468 ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC12418764/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC9135416/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC8161007/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
pnas.org. https://www.pnas.org/doi/10.1073/pnas.1219451110 ↩︎ ↩︎ ↩︎
consumerlab.com. https://www.consumerlab.com/answers/akkermansia-muciniphila-health-benefits-and-safety/akkermansia-muciniphila/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
mdpi.com. https://www.mdpi.com/2072-6643/17/15/2516 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC11174979/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
mdpi.com. https://www.mdpi.com/2072-6643/14/4/764 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
preprints.org. https://www.preprints.org/manuscript/202509.2367 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC6699990/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
frontiersin.org. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1524563/full ↩︎ ↩︎
sochob.cl. https://www.sochob.cl/web1/wp-content/uploads/2019/12/Supplementation-with-Akkermansia-muciniphila-in-overweight-and-obese-human-volunteers-a-proof-of-concept-exploratory-study.pdf ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
wur.nl. https://research.wur.nl/en/publications/supplementation-with-akkermansia-muciniphila-in-overweight-and-ob/ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC12628924/ ↩︎ ↩︎
seerave.org. https://seerave.org/antibiotics-affect-the-efficacy-of-immunotherapy/ ↩︎ ↩︎ ↩︎
gustaveroussy.fr. https://www.gustaveroussy.fr/en/antibiotics-affect-efficacy-immunotherapy ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pubmed.ncbi.nlm.nih.gov/29097494/ ↩︎ ↩︎ ↩︎ ↩︎
frontiersin.org. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1528594/full ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC9330544/ ↩︎ ↩︎
bmj.com. https://jitc.bmj.com/content/13/Suppl_2/A561 ↩︎ ↩︎ ↩︎
clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06865521 ↩︎ ↩︎
clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05865730 ↩︎ ↩︎
rsc.org. https://pubs.rsc.org/en/content/articlelanding/2021/fo/d1fo00115a ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
frontiersin.org. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1650807/full ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05738746 ↩︎ ↩︎
oaepublish.com. https://www.oaepublish.com/articles/mrr.2023.81 ↩︎ ↩︎ ↩︎
plos.org. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0173004 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC11297771/ ↩︎ ↩︎ ↩︎ ↩︎
tandfonline.com. https://www.tandfonline.com/doi/full/10.1080/19490976.2022.2078619 ↩︎ ↩︎ ↩︎ ↩︎
biorxiv.org. https://www.biorxiv.org/content/10.64898/2026.03.18.708496v1.full.pdf ↩︎ ↩︎ ↩︎
isappscience.org. https://isappscience.org/pasteurized-akkermansia-muciniphila-as-a-postbiotic-efsa-approval-and-beyond/ ↩︎ ↩︎ ↩︎ ↩︎
nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC8409316/ ↩︎ ↩︎ ↩︎
echemi.com. https://www.echemi.com/cms/2634523.html ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
ipa-biotics.org. https://ipa-biotics.org/hpa-china-news-october-2025/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
cirs-group.com. http://www.cirs-group.com/en/food/expanded-use-of-pasteurised-akkermansia-in-the-eu-now-permitted-for-adolescents-aged-12-and-above ↩︎ ↩︎ ↩︎
researchgate.net. https://www.researchgate.net/publication/395838728_Safety_of_an_extension_of_use_of_pasteurised_Akkermansia_muciniphila_as_a_novel_food_pursuant_to_Regulation_EU_20152283 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
lih.lu. https://researchportal.lih.lu/en/publications/safety-of-an-extension-of-use-of-pasteurised-akkermansia-muciniph/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
pendulumlife.com. https://pendulumlife.com/blogs/news/what-are-colony-forming-units-and-active-fluorescent-units ↩︎ ↩︎ ↩︎ ↩︎
pendulumlife.com. https://pendulumlife.com/products/pendulum-glucose-control-probiotic-blood-sugar ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
pendulumlife.co.nz. https://pendulumlife.co.nz/pages/pendulum-akkermansia ↩︎ ↩︎ ↩︎ ↩︎
pendulumlife.com. https://pendulumlife.com/blogs/news/what-is-akkermansia-muciniphila-all-your-questions-answered ↩︎ ↩︎ ↩︎ ↩︎
seed.com. https://seed.com/cultured/seed-vs-pendulum-probiotics-comparison-guide/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
pendulumlife.com. https://pendulumlife.com/products/pendulum-akkermansia-probiotic-gut-health ↩︎ ↩︎ ↩︎
nhc.com. https://www.nhc.com/products/glucose-control-by-pendulum ↩︎ ↩︎ ↩︎
pureformulas.com. https://www.pureformulas.com/product/glucose-control-pro-by-pendulum/1000060802 ↩︎ ↩︎ ↩︎
fullscript.com. https://fullscript.com/catalog/products/glucose-control-pro ↩︎ ↩︎
iprogressivemed.com. https://store.iprogressivemed.com/product/glucose-control-pro-60-caps-by-pendulum/ ↩︎ ↩︎
mdpi.com. https://www.mdpi.com/1422-0067/26/23/11602 ↩︎ ↩︎ ↩︎
frontiersin.org. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.01137/full ↩︎